GO
Loading...

Vivus Inc

More

  • Nasdaq stocks posting largest volume increases Thursday, 18 Sep 2014 | 6:04 PM ET

    The shares fell$. 10 or 1.1 percent to $8.70. Eastern Virginia Bankshares Inc.: Approximately 150,700 shares changed hands, a 1,515.3 percent increase over its 65- day average volume. The shares fell$. 04 or. 6 percent to $6.21.

  • Rite Aid and Pier 1 are big market movers Thursday, 18 Sep 2014 | 5:25 PM ET

    NEW YORK— Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:. Rite Aid Corp., down $1.23 to $5.41. Pier 1 Imports Inc., down $2.88 to $12.66.

  • The drug, developed by Vivus Inc, is marketed in the United States and Canada by Auxilium Pharmaceuticals Inc. Vivus' stock was up about 13 percent at $4.40 in afternoon trading.

  • The drug was developed by Auxilium Pharmaceuticals Inc and Vivus Inc.. Vivus owns the worldwide development and commercial rights to Stendra for use in sexual dysfunction, with the exception of certain Asian countries in the Pacific Rim.

  • NEW YORK, Sept 18- U.S. stocks were higher in afternoon trading on Thursday, with the S&P 500 hitting a record peak a day after the U.S.

  • Most active Nasdaq-traded stocks Thursday, 18 Sep 2014 | 1:18 PM ET

    Apple Inc. rose. 2 percent to $101.79 with 35,902,100 shares traded. Facebook Inc. rose. 7 percent to $77.00 with 22,472,500 shares traded. Gilead Sciences Inc. rose 2.0 percent to $105.93 with 16,071,400 shares traded.

  • The drug, developed by Vivus Inc, is marketed in the United States and Canada by Auxilium Pharmaceuticals Inc. Vivus' stock was up about 13 percent at $4.40 in afternoon trading.

  • US STOCKS-Dow, S&P hit record as financials climb Thursday, 18 Sep 2014 | 1:14 PM ET

    NEW YORK, Sept 18- U.S. stocks were higher in afternoon trading Thursday, with the Dow and S&P 500 hitting fresh record highs after the U.S. Goldman Sachs, up 1.6 percent to $187.84, was the top boost to the Dow.

  • US STOCKS-S&P hits record on Fed support; financials lead Thursday, 18 Sep 2014 | 11:42 AM ET

    NEW YORK, Sept 18- U.S. stocks were rising in late morning trading on Thursday, with the S&P 500 hitting a record high a day after the U.S. However, the central bank's outlook included forecasts for higher-than-expected rates in 2015 and 2016, which helped financial stocks lead gains on Wall Street.

  • The largest percentage gainer on the New York Stock Exchange was Penn West Petroleum, up 11.54 percent, while the largest decliner was Pier 1 Imports, down 17.57 percent a day after it slashed its full-year earnings forecast.

  • *Futures up: Dow 44 pts, S&P 6 pts, Nasdaq 13 pts. NEW YORK, Sept 18- U.S. stocks were set to rise at the open on Thursday, with the S&P 500 on track to test resistance at its record high a day after the U.S.

  • FDA OKs faster-acting label for ED drug Stendra Thursday, 18 Sep 2014 | 8:21 AM ET

    Federal regulators have approved a new label for Vivus' impotence drug, stating that it becomes effective in half the time that the previous label had stated. But Vivus has sought a new label after finding in studies that some patients were able to have sex as little as 15 minutes.

  • Sept 18- An erectile dysfunction drug that reduces by half the time patients need to take the pill before sexual activity has been approved by the U.S. Food and Drug Administration.

  • Business Highlights Thursday, 11 Sep 2014 | 5:57 PM ET

    Launched in 2006 to a flurry of media coverage, the Mountain View, California- based company seemed to have every strategic advantage: millions in startup cash, celebrity endorsements, and a chief executive married to one of the co-founders of Google. RadioShack warns of possible Chapter 11 bankruptcy.

  • FDA panel backs Novo Nordisk injection for obesity Thursday, 11 Sep 2014 | 4:16 PM ET

    The FDA first approved the drug, liraglutide, under the brand name Victoza in 2010 as a daily injection for type 2 diabetes, in which the body does not properly use insulin. Danish drugmaker Novo Nordisk now wants the FDA to approve the drug as an obesity treatment based on company studies showing significant weight loss in most patients.

  • FDA approves weight-loss drug Contrave Thursday, 11 Sep 2014 | 6:53 AM ET

    Contrave joins two similar drugs from Arena Pharmaceuticals and Vivus Inc. which FDA approved in 2012 after a 13- year drought of new prescription weight-loss medicines. But sales of Vivus' Qsymia and Arena's Belviq have been far below expectations due to limited insurance coverage and high out-of-pocket costs for patients.

  • Long-awaited diet pill gets U.S. approval Wednesday, 10 Sep 2014 | 9:00 PM ET

    Sept 10- A new diet pill Contrave got approval to be sold in the United States on Wednesday, only the third obesity treatment in more than a decade to win approval from the Food and Drug Administration.

  • WASHINGTON, Sept 9- Novo Nordisk's drug liraglutide appears effective in treating obesity, though safety questions remain, according to a preliminary assessment by reviewers at the U.S. Food and Drug Administration.

  • Lightning Round: Akamai, GE & more Tuesday, 15 Jul 2014 | 6:49 PM ET

    It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Orexigen shares hit by FDA delay in obesity drug Wednesday, 11 Jun 2014 | 10:07 AM ET

    Orexigen Therapeutics shares fell 15 percent after the FDA delayed its decision on the drug pending post-marketing safety monitoring requirements.